{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:11:59Z","timestamp":1790061119979,"version":"4.0.1"},"reference-count":75,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This review aims to examine the complex interaction between dyslipidemia, platelet function, and related drug treatments. In particular, the manuscript provides an overview of the effects of major hypolipidemic drugs on platelet function. Indeed, growing evidence supports the view that statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl also act as antithrombotics. It is known that platelets play a key role not only in the acute phase of coronary syndromes but also in the early phase of atherosclerotic plaque formation. The goal of cholesterol-lowering therapy is to reduce cardiovascular events. The direct effects of cholesterol-lowering drugs are widely described in the literature. Lowering LDL-c (low-density lipoprotein cholesterol) by 1 mmol\/L results in a 22\u201323% reduction in cardiovascular risk. Numerous studies have examined the direct antithrombotic effects of these drugs on platelets, endothelium, monocytes, and smooth muscle cells, and thus, potentially independent of blood LDL-cholesterol reduction. We reviewed in vitro and in vivo studies evaluating the complex interaction between hypercholesterolemia, hypertriglyceridemia, platelet function, and related drug treatments. First, we discussed the role of statins in modulating platelet activation. Discontinuation of statin therapy was associated with increased cardiovascular events with increased ox-LDL, P-selectin, and platelet aggregation. The effect of PCSK9-I (inhibitors of proprotein convertase subtilisin\/kexin type 9, PCSK9 involved in the degradation of LDL receptors in the liver) was associated with a statistically significant reduction in platelet reactivity, calculated in P2Y12 reaction units (PRU), in the first 14 days and no difference at 30 days compared to placebo. Finally, in patients with hypertriglyceridemia, the REDUCE-IT study showed that icosapent ethyl (an ethyl ester of eicosapentaenoic acid that reduces triglyceride synthesis and improves triglyceride clearance) resulted in a 25% reduction in ischemic events and cardiovascular death. However, to date, there is not yet clear clinical evidence that the direct antithrombotic effects of the drugs may have a beneficial impact on outcomes independently from the reduction in LDL-C or triglycerides.<\/jats:p>","DOI":"10.3390\/ijms241411739","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:47:03Z","timestamp":1690159623000},"page":"11739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function"],"prefix":"10.3390","volume":"24","author":[{"given":"Assunta","family":"Di Costanzo","sequence":"first","affiliation":[{"name":"Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-6487","authenticated-orcid":false,"given":"Ciro","family":"Indolfi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabato","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Anna Maria","family":"Spaccarotella","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"ref_1","first-page":"226","article-title":"Are we ready for a gender-specific approach in interventional cardiology?","volume":"286","author":"Niccoli","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.hlc.2013.03.001","article-title":"Pathophysiology of atherosclerosis plaque progression","volume":"22","author":"Sakakura","year":"2013","journal-title":"Heart Lung Circ."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., and Collins, R. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.2459\/JCM.0000000000001440","article-title":"Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: An expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology","volume":"24","author":"Spaccarotella","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_5","first-page":"481","article-title":"Perrone Filardi, Dalla rivoluzione delle statine alla terapia di silenziamento genico: 50 anni di evoluzione nella terapia dell\u2019ipercolesterolemia","volume":"23","author":"Romeo","year":"2022","journal-title":"G. Ital. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijcard.2017.04.107","article-title":"Transcatheter aortic valve implantation in patients at intermediate surgical risk","volume":"243","author":"Spaccarotella","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_7","first-page":"18","article-title":"Platelet reactivity tests: Why they are useful and which ones to use","volume":"8","year":"2010","journal-title":"EJ ESC Counc. Cardiol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1084\/jem.20012044","article-title":"A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation","volume":"196","author":"Massberg","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1172\/JCI27196","article-title":"Platelets in inflammation and atherogenesis","volume":"115","author":"Gawaz","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1074\/jbc.M208894200","article-title":"platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells","volume":"278","author":"Nassar","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/blood.V99.10.3613","article-title":"Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface","volume":"99","author":"Sachais","year":"2002","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low Density Lipoprotein Oxidation and Its Pathobiological Significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11010-021-04307-x","article-title":"Atherosclerosis: Nexus of vascular dynamics and cellular cross talks","volume":"477","author":"Dasagrandhi","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1038\/s41598-021-89967-x","article-title":"Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: A meta-analysis of 35 studies and 6427 patients","volume":"11","author":"Polimeni","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-Mediated Thrombosis","volume":"118","author":"Gurbel","year":"2016","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.ATV.0000095974.95122.EC","article-title":"Platelets in Inflammation and Thrombosis","volume":"23","author":"Wagner","year":"2003","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2003-40673","article-title":"Role of Platelets in the Pathophysiology of Acute Coronary Syndrome","volume":"3","author":"Massberg","year":"2003","journal-title":"Semin. Vasc. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0033-0620(87)90011-9","article-title":"Platelet activation by plasma lipoproteins","volume":"30","author":"Aviram","year":"1987","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/jcp.2004.025387","article-title":"Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: An Indian scenario","volume":"59","author":"Khandekar","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"ref_21","first-page":"e25884","article-title":"Hyperlipidemia and Platelet Parameters: Two Sides of the Same Coin","volume":"14","author":"Singh","year":"2022","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2257.2004.00634.x","article-title":"Platelet larger cell ratio (P-LCR) in patients with dyslipidemia","volume":"26","author":"Grotto","year":"2004","journal-title":"Clin. Lab. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1081881","DOI":"10.3389\/fphys.2022.1081881","article-title":"Vascular smooth muscle cells in intimal hyperplasia, an update","volume":"13","author":"Bechelli","year":"2023","journal-title":"Front. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0735-1097(99)00526-4","article-title":"Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury","volume":"35","author":"Indolfi","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.0000034047.70205.97","article-title":"Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation","volume":"106","author":"Indolfi","year":"2002","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH03-02-0111","article-title":"Platelet hyperactivity after statin treatment discontinuation","volume":"90","author":"Pasqui","year":"2003","journal-title":"Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/dmd.108.024570","article-title":"Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin","volume":"37","author":"Niessen","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2005.11.058","article-title":"Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients with the Metabolic Syndrome (from the PAR-1 Inhibition by Statins [PARIS] Study)","volume":"97","author":"Serebruany","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chiva-Blanch, G., Laake, K., Myhre, P., Bratseth, V., Arnesen, H., Solheim, S., Badimon, L., and Seljeflot, I. (2017). Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172558"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1160\/TH13-03-0238","article-title":"Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells","volume":"110","author":"Suades","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.CIR.0000153810.81187.7D","article-title":"Short-Term Treatment with Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients","volume":"111","author":"Sanguigni","year":"2005","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0735-1097(02)02718-3","article-title":"Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy","volume":"41","author":"Semb","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2008-05-155978","article-title":"Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK\u2013dependent integrin outside-in retractile signaling pathway","volume":"113","author":"Flevaris","year":"2009","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/157340641202160208195923","article-title":"Role of Calcium in Platelet Activation: Novel Insights and Pharmacological Implications","volume":"12","author":"Davlouros","year":"2016","journal-title":"Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.2174\/092986710792065018","article-title":"Regulators of platelet cAMP levels: Clinical and therapeutic implications","volume":"17","author":"Noe","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects from Cerebral Ischemia in Normocholesterolemic Mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Szczuko, M., Kozio\u0142, I., Kotl\u0119ga, D., Brodowski, J., and Drozd, A. (2021). The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111644"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000145327","article-title":"Statin Potentiates Human Platelet eNOS Activity without Enhancing eNOS mRNA and Protein Levels","volume":"26","author":"Yemisci","year":"2008","journal-title":"Cerebrovasc. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cpt.1075","article-title":"Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease","volume":"104","author":"Tacconelli","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijcard.2016.09.122","article-title":"Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells","volume":"227","author":"Becher","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2125.2007.03080.x","article-title":"Ezetimibe\u2019s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin","volume":"65","author":"Hussein","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1161\/01.CIR.99.25.3315","article-title":"Urokinase receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice","volume":"99","author":"Piguet","year":"1999","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.14740\/jocmr3901","article-title":"Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients with Dyslipidemia","volume":"11","author":"Tano","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: From the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvaa024","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: A systematic review and network meta-analysis","volume":"7","author":"Guedeney","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sundararaman, S.S., D\u00f6ring, Y., and van der Vorst, E.P.C. (2021). PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070793"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"934914","DOI":"10.3389\/fcvm.2022.934914","article-title":"Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_55","first-page":"1254","article-title":"Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic car-diovascular disease: A randomised, double-blind, placebo-controlled study","volume":"18","author":"Franchi","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.21037\/cdt-20-684","article-title":"Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: Rationale and design of the randomized, placebo-controlled HUYGENS study","volume":"11","author":"Nicholls","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction","volume":"327","author":"Ueki","year":"2022","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.20517\/2574-1209.2020.71","article-title":"The local effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9) on the inflammatory atheroma: Beyond LDL cholesterol lowering","volume":"5","author":"Xiong","year":"2021","journal-title":"Vessel Plus"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cammisotto, V., Baratta, F., Castellani, V., Bartimoccia, S., Nocella, C., D\u2019erasmo, L., Cocomello, N., Barale, C., Scicali, R., and Di Pino, A. (2021). Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137193"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up","volume":"30","author":"Barale","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gareri, C., Polimeni, A., Giordano, S., Tamm\u00e8, L., Curcio, A., and Indolfi, C. (2022). Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133884"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: A pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Barale, C., Melchionda, E., Morotti, A., and Russo, I. (2021). PCSK9 Biology and Its Role in Atherothrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115880"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCOUTCOMES.115.002436","article-title":"Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?","volume":"9","author":"Bartlett","year":"2016","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e015801","DOI":"10.1161\/JAHA.119.015801","article-title":"Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis","volume":"9","author":"Arca","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: Results from a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer","volume":"41","author":"Taieb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2023.03.013","article-title":"The association between platelet reactivity and lipoprotein levels in Framingham Heart Study participants","volume":"225","author":"Nkambule","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109392","DOI":"10.1016\/j.intimp.2022.109392","article-title":"Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPK\u03b1 signaling pathway","volume":"113","author":"Liu","year":"2022","journal-title":"Int. Immunopharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:16:25Z","timestamp":1760127385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":75,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411739"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411739","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}